Allogene TherapeuticsvsJohnson & Johnson

ALLO and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

ALLO

Allogene Therapeutics, Inc.

$0.63

Value $217M

-5.97%
ALLO's page

Allogene Therapeutics (ALLO) has a market value of $217M and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, ALLO moved -50.0% and JNJ +36.6%. Dividend yield: ALLO none, JNJ 1.95%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ALLO$217M

    JNJ$652B

    JNJ is 2,997 times ALLO

  • Revenue, 12 months

    ALLO$4.6M

    JNJ$99.3B

    JNJ is 21,408 times ALLO

  • Net income, 12 months

    ALLO-$174M

    JNJ$16.1B

  • Operating margin

    ALLO-4,099.3%

    JNJ–

  • ROIC

    ALLO-43.8%

    JNJ12.4%

    56.2 points apart

  • P/E

    ALLO–

    JNJ40.5

  • Dividend yield

    ALLO0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    ALLO-96.7%

    JNJ+90.9%

    187.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ALLO-96.7%

JNJ+90.9%

010020020222023202420252026
Returns by period
PeriodALLOWith dividendsJNJWith dividends
1 year since November 19, 2025-50.0%Price -50.0%+36.6%Price +33.6%
3 years since November 20, 2023-78.9%-40.5% a yearPrice -78.9%+94.9%+24.9% a yearPrice +80.4%
5 years since November 19, 2021-96.7%-49.3% a yearPrice -96.7%+90.9%+13.8% a yearPrice +66.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ALLOAllogene TherapeuticsJNJJohnson & Johnson

Valuation

ALLOJNJ
Valuation
Price$0.63$270.47
Market value$217M$652B
Enterprise value (EV)–$679B
P/E–40.5
P/E, 5-year median–21.9
P/B0.68.0
EV/EBIT–38.3
Free cash flow yield–3.2%

Results and growth

ALLOJNJ
Results and growth
Revenue, 12 months$4.6M$99.3B
Net income, 12 months-$174M$16.1B
Free cash flow, 12 months-$109M$20.6B
Earnings per share, 12 months-$0.63$6.59
Revenue growth, year on year-100.0%6.1%
Revenue growth a year, past–+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

ALLOJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin-4,099.3%–
Net margin-3,760.0%16.2%
ROIC-43.8%12.4%
ROE-50.8%19.7%

Balance sheet

ALLOJNJ
Balance sheet
Cash$389M$17.2B
Total debt–$44.7B
Net debt / EBITDA–1.1
Interest cover-142.5×18.0×

Dividends and buybacks

ALLOJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ALLO or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Allogene Therapeutics or Johnson & Johnson?

By market value, Johnson & Johnson ($652B) is about 2,997.1 times Allogene Therapeutics ($217M), at today's prices.

How did ALLO and JNJ stock do over the last 5 years?

Since November 19, 2021, ALLO's price moved -96.7% and JNJ's +66.0%. With dividends: ALLO -96.7% (-49.3% a year), JNJ +90.9% (+13.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, ALLO or JNJ?

The dividend yield at today's price is none for Allogene Therapeutics and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Allogene Therapeutics or Johnson & Johnson?

Over the last twelve months, the net margin was -3,760.0% for Allogene Therapeutics and 16.2% for Johnson & Johnson, and the operating margin -4,099.3% and –. Revenue was $4.6M and $99.3B.

Which is the better investment, Allogene Therapeutics or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.